SPRO Share Price Performance
US$1.19
-1.11 (-48.26%)
70.3% undervalued intrinsic discount
US$4.00
Fair Value
Price US$1.19
AnalystConsensusTarget US$4.00
Fair ValueUS$4.00
Share Pricen/a
Seeking Alpha • Jul 14
Spero Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
SPRO Community Narratives
AN
Fair Value
·Fair Value US$4 70.3% undervalued intrinsic discount
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
Key Takeaways Successful late-stage results and strategic partnerships could propel revenue growth, reduce fixed costs, and stabilize near-term cash flow. Favorable regulatory landscape and market demand for novel antibiotics position the company for sustained expansion and margin improvement.Read more
AN
US$4
70.3% undervalued intrinsic discount
Fair Value
Profit Margin
16.06%
Future PE
129.09x
Price in 2028
US$4.8
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
Fair Value: US$4 70.3% undervalued intrinsic discount
22 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Spero Therapeutics, Inc. Key Details
About SPRO
- Founded
- 2013
- Employees
- 25
- CEO
- WebsiteView website
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
